Literature DB >> 18941111

MicroRNA-17-92 down-regulates expression of distinct targets in different B-cell lymphoma subtypes.

Mika Inomata1, Hiroyuki Tagawa, Yong-Mei Guo, Yoshihiro Kameoka, Naoto Takahashi, Kenichi Sawada.   

Abstract

Aberrant overexpression of the miR-17-92 polycistron is strongly associated with B-cell lymphomagenesis. Recent studies have shown that miR-17-92 down-regulates the proapoptotic protein Bim, leading to overexpression of Bcl2, which likely plays a key role in lymphomagenesis. However, the fact that Jeko-1 cells derived from mantle cell lymphoma exhibit both homozygous deletion of BIM and overexpression of miR-17-92 suggests other targets are also involved in B-cell lymphomagenesis. To identify essential target(s) of miR-17-92 in lymphomagenesis, we first transfected miR-17-92 into 2 genetically distinct B-cell lymphoma cell lines: Raji, which overexpress c-Myc, and SUDHL4, which overexpress Bcl2. Raji transfected with miR-17-19b-1 exhibited down-regulated expression of Bim and a slight up-regulation in Bcl2 expression. On the other hand, SUDHL4 transfectants showed aggressive cell growth reflecting facilitated cell cycle progression at the G(1) to S transition and decreased expression of CDKN1A mRNA and p21 protein (CDKN1A/p21) that was independent of p53 expression. Conversely, transfection of antisense oligonucleotides against miR-17 and miR-20a into Jeko-1 led to up-regulation of CDKN1A/p21, resulting in decreased cell growth with G(1) to S arrest. Thus, CDKN1A/p21 appears to be an essential target of miR-17-92 during B-cell lymphomagenesis, which suggests the miR-17-92 polycistron has distinct targets in different B-cell lymphoma subtypes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18941111     DOI: 10.1182/blood-2008-07-163907

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  104 in total

1.  Pervasive and cooperative deadenylation of 3'UTRs by embryonic microRNA families.

Authors:  Edlyn Wu; Caroline Thivierge; Mathieu Flamand; Geraldine Mathonnet; Ajay A Vashisht; James Wohlschlegel; Marc R Fabian; Nahum Sonenberg; Thomas F Duchaine
Journal:  Mol Cell       Date:  2010-11-24       Impact factor: 17.970

Review 2.  Shielding the messenger (RNA): microRNA-based anticancer therapies.

Authors:  Elena Sotillo; Andrei Thomas-Tikhonenko
Journal:  Pharmacol Ther       Date:  2011-04-14       Impact factor: 12.310

3.  EBV and human microRNAs co-target oncogenic and apoptotic viral and human genes during latency.

Authors:  Kasandra J Riley; Gabrielle S Rabinowitz; Therese A Yario; Joseph M Luna; Robert B Darnell; Joan A Steitz
Journal:  EMBO J       Date:  2012-03-30       Impact factor: 11.598

4.  Cross-analysis of gene and miRNA genome-wide expression profiles in human fibroblasts at different stages of transformation.

Authors:  Paola Ostano; Silvia Bione; Cristina Belgiovine; Ilaria Chiodi; Chiara Ghimenti; A Ivana Scovassi; Giovanna Chiorino; Chiara Mondello
Journal:  OMICS       Date:  2012 Jan-Feb

5.  Multiple E2F-induced microRNAs prevent replicative stress in response to mitogenic signaling.

Authors:  María J Bueno; Marta Gómez de Cedrón; Usua Laresgoiti; José Fernández-Piqueras; Ana M Zubiaga; Marcos Malumbres
Journal:  Mol Cell Biol       Date:  2010-04-19       Impact factor: 4.272

Review 6.  miRNAs in normal and malignant B cells.

Authors:  Ai Kotani; Ratanakanit Harnprasopwat; Takae Toyoshima; Toyotaka Kawamata; Arinobu Tojo
Journal:  Int J Hematol       Date:  2010-07-08       Impact factor: 2.490

7.  Dietary Indoles Suppress Delayed-Type Hypersensitivity by Inducing a Switch from Proinflammatory Th17 Cells to Anti-Inflammatory Regulatory T Cells through Regulation of MicroRNA.

Authors:  Narendra P Singh; Udai P Singh; Michael Rouse; Jiajia Zhang; Saurabh Chatterjee; Prakash S Nagarkatti; Mitzi Nagarkatti
Journal:  J Immunol       Date:  2015-12-28       Impact factor: 5.422

8.  MicroRNA-32 upregulation by 1,25-dihydroxyvitamin D3 in human myeloid leukemia cells leads to Bim targeting and inhibition of AraC-induced apoptosis.

Authors:  Elzbieta Gocek; Xuening Wang; Xiuping Liu; Chang-Gong Liu; George P Studzinski
Journal:  Cancer Res       Date:  2011-08-04       Impact factor: 12.701

9.  Structure and activity of putative intronic miRNA promoters.

Authors:  Alex Mas Monteys; Ryan M Spengler; Ji Wan; Luis Tecedor; Kimberly A Lennox; Yi Xing; Beverly L Davidson
Journal:  RNA       Date:  2010-01-14       Impact factor: 4.942

10.  miR-19 is a key oncogenic component of mir-17-92.

Authors:  Virginie Olive; Margaux J Bennett; James C Walker; Cong Ma; Iris Jiang; Carlos Cordon-Cardo; Qi-Jing Li; Scott W Lowe; Gregory J Hannon; Lin He
Journal:  Genes Dev       Date:  2009-12-15       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.